Alteogen, the market capitalization leader on South Korea's KOSDAQ exchange, closed 3.75% higher at 277,000 won on the trading day discussed, marking its fourth consecutive session of gains ahead of the company's second-quarter earnings release. The biotech firm announced a technology export agreement with a global pharmaceutical company valued at up to $365 million (approximately 521.9 billion won), its third such contract in 2025. The rally was driven by the new licensing deal and stronger-than-expected sales of MSD's Keytruda Hylecta, a subcutaneous formulation that incorporates Alteogen's ALT-B4 technology and generated $463 million in second-quarter revenue. Analysts attribute the stock's momentum to the prospect of additional licensing agreements before year-end and expanding royalty income from Keytruda's subcutaneous conversion. The upward movement began on July 31 when South Korean equity markets rebounded broadly, with Alteogen benefiting from renewed capital inflows into KOSDAQ biotech stocks.
Alteogen Signs $365 Million Technology Export Contract
Alteogen disclosed an exclusive technology export agreement with an undisclosed global pharmaceutical company to develop and commercialize one biopharmaceutical product as a subcutaneous formulation using ALT-B4, a core component of its Hybrozyme platform. The contract includes upfront payments and milestone fees across development, regulatory approval, and commercialization stages, with a maximum value of $365 million (approximately 521.9 billion won). Upon commercialization, Alteogen will receive royalties calculated as a percentage of net sales. The company did not disclose the contracting party or the target product.
This marks Alteogen's third Hybrozyme platform technology export in 2025. In January, the company signed a contract worth up to $285 million with Tesaro, a subsidiary of GlaxoSmithKline (GSK). In March, Alteogen entered an agreement with Biogen covering two products with a maximum value of $579 million. The combined maximum contract value for the three 2025 deals totals $1.229 billion, approximately 1.8 trillion won.
MSD Reports $463 Million Keytruda Hylecta Q2 Sales
MSD announced during its second-quarter conference call that Keytruda Hylecta, which utilizes Alteogen's ALT-B4 technology, generated $463 million in sales during the second quarter, more than tripling the first-quarter figure of $128 million. The result exceeded Wall Street consensus estimates of $283 million by approximately 64%. As product sales increase, Alteogen's royalty income rises proportionally under the licensing structure.
Alteogen has not yet released its second-quarter earnings. Last year, the company filed its semi-annual report on August 13. According to financial data provider FnGuide, the consensus forecast for Alteogen's second quarter is 65.5 billion won in revenue and 24.3 billion won in operating profit. Revenue is expected to increase 251.2% year-over-year, while operating profit is projected to swing from a 400 million won loss to profitability.
Analysts Highlight Additional Contract Potential and Royalty Growth
Securities analysts are monitoring the possibility of further technology licensing agreements before year-end and the acceleration of royalty income expansion tied to Keytruda's subcutaneous formulation conversion. One biotech research analyst at a securities firm stated that additional technology transfer deals are being discussed beyond the recently announced contract, and confirmation of follow-up agreements within the year could drive further stock price appreciation. The analyst noted that Keytruda Hylecta's second-quarter sales grew faster than market expectations and MSD's subcutaneous conversion targets have become more concrete, increasing the likelihood that Alteogen's royalty income will expand sooner than anticipated.
The analyst also identified favorable supply-and-demand factors, pointing to recent capital inflows into KOSDAQ stocks independent of KOSPI movements. The analyst remarked that during the first half of the year, KOSDAQ was neglected when KOSPI rose and declined alongside KOSPI during downturns, reflecting supply-side weakness unrelated to corporate fundamentals. While it is premature to conclude that a long-term rotation into KOSDAQ biotech stocks has begun, the analyst assessed the recent KOSDAQ rebound and fund migration as meaningful and positive developments.
FAQ
What did Alteogen announce on the trading day discussed?
Alteogen announced an exclusive technology export contract with a global pharmaceutical company to develop and commercialize one biopharmaceutical product using its ALT-B4 technology. The agreement is valued at up to $365 million (approximately 521.9 billion won), including upfront payments and milestone fees, plus royalties upon commercialization.
How much revenue did Keytruda Hylecta generate in the second quarter?
MSD reported that Keytruda Hylecta generated $463 million in second-quarter sales, more than tripling the first-quarter figure of $128 million and exceeding Wall Street consensus estimates of $283 million by approximately 64%.
What is the total maximum value of Alteogen's 2025 technology export contracts?
Alteogen signed three technology export contracts in 2025 with maximum values of $285 million (GSK subsidiary Tesaro in January), $579 million (Biogen in March), and $365 million (undisclosed partner on the trading day discussed). The combined maximum contract value is $1.229 billion, approximately 1.8 trillion won.
